Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality (AMPLCaRe)
Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality: A Randomized Placebo Controlled Clinical Trial
Sponsor: Gateway for Cancer Research
A PHASE3 clinical study on Non Small Cell Lung Cancer, this trial is completed. The trial is conducted by Gateway for Cancer Research and has accumulated 12 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)The trial employs a two-armed parallel placebo controlled trial design whereby patients with a diagnosis of non small cell lung cancer are randomized to receive either 20 mg of melatonin nightly or an identically matched placebo. All patients will be followed for two years with primary outcomes assessed at a two year time point and secondary outcomes evaluated throughout the course of the trial.
The trial employs a two-armed parallel placebo controlled trial design whereby patients with a diagnosis of non small cell lung cancer are randomized to receive either 20 mg of melatonin nightly or an identically matched placebo. All patients will be followed for two years with primary outcomes assessed at a two year time point and secondary outcomes evaluated throughout the course of the trial.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2019 — May 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gateway for Cancer Research
- Lotte & John Hecht Memorial Foundation
- The Canadian College of Naturopathic Medicine
- The Ottawa Hospital
For direct contact, visit the study record on ClinicalTrials.gov .